Research analysts covering OKYO Pharma.
Recent press releases and 8-K filings for OKYO.
OKYO Pharma CEO to Present on Urcosimod at OIS XV
OKYO
New Projects/Investments
- OKYO Pharma's CEO, Gary S. Jacob, Ph.D., is scheduled to present at the Ophthalmology Innovation Summit (OIS) XV on Saturday, November 22, 2025, from 8:30-9:30 AM PT.
- The presentation will focus on urcosimod, the company's lead investigational drug candidate for neuropathic corneal pain (NCP).
- Following positive top-line results from a Phase 2 trial in NCP, OKYO is advancing urcosimod toward a 120-patient multi-center clinical trial.
- Neuropathic corneal pain is an ocular condition that currently has no FDA-approved therapy, indicating a major unmet medical need.
Nov 18, 2025, 1:30 PM
OKYO Pharma to Present Urcosimod Updates at BIO-Europe 2025
OKYO
New Projects/Investments
- OKYO Pharma's CEO, Gary S. Jacob, Ph.D., is scheduled to present at the 33rd Annual BIO-Europe partnering conference in Vienna, Austria, from November 3-5, 2025.
- The presentation will highlight urcosimod, the company's lead investigational candidate, and provide updates on its recently completed Phase 2 clinical trial for neuropathic corneal pain (NCP).
- OKYO's management team will also participate in one-on-one partnering meetings to discuss clinical milestones, including positive clinical data for urcosimod and its accelerated clinical development program.
- Urcosimod previously demonstrated clear statistical significance in multiple endpoints in a 240-patient Phase 2 trial for dry eye disease and has just completed a Phase 2 trial for NCP.
Oct 29, 2025, 11:00 AM
OKYO Pharma Executive Chairman Acquires Shares
OKYO
- Gabriele Cerrone, Executive Chairman of OKYO Pharma, through Panetta Partners Limited, acquired 210,000 of the Company’s ordinary shares on NASDAQ.
- This acquisition brings his total holding to 10,382,677 shares.
- OKYO Pharma is an ophthalmology-focused bio-pharmaceutical company developing urcosimod to treat neuropathic corneal pain (NCP) and dry eye disease.
- Urcosimod has completed a Phase 2 trial for dry eye disease, showing statistical significance in multiple endpoints, and recently completed a Phase 2 trial for neuropathic corneal pain.
Oct 16, 2025, 12:33 PM
OKYO Pharma Announces Next Clinical Trial Stage for Urcosimod in Neuropathic Corneal Pain
OKYO
New Projects/Investments
- OKYO Pharma LTD announced plans for the next stage of clinical development for urcosimod to treat neuropathic corneal pain (NCP).
- This decision follows positive topline data from a Phase 2 proof-of-concept trial in July, where 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in NCP.
- The company will initiate a multiple-ascending-dose (MAD) clinical trial enrolling approximately 100 NCP patients across several U.S. sites to identify the optimal registration dose for future Phase 3 trials.
- Topline data from this trial is anticipated in 2026, and OKYO is engaging with the FDA regarding registration requirements, leveraging urcosimod's Fast-Track designation.
Sep 22, 2025, 12:30 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more